Kétamine et dépression : vers de nouvelles perspectives thérapeutiques en soins de support ?

Abdallah CG, Fasula M, Kelmendi B, et al (2012) Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT 28:157–161

Akinfiresoye L, Tizabi Y (2013) Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) [Internet]. 4 juin [cité 1 juill 2013]

Autry AE, Adachi M, Nosyreva E, et al (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91–95

Berman RM, Cappiello A, Anand A, et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354

Beurel E, Song L, Jope RS (2011) Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 16:1068–1070

Blank K, Robison J, Doherty E, et al (2001) Life-sustaining treatment and assisted death choices in depressed older patients. J Am Geriatr Soc 49:153–161

Bordet R, Thomas P, Dupuis B, et al (1999) Délai d’action des antidépresseurs, des données expérimentales à la prise en charge thérapeutique. La Lettre du pharmacologue 13, no 7

Bricard C, Boidein F (2001) Revue générale de l’utilisation du méthylphénidate. Lyon Pharmaceutique 52:7–33

Caraceni A, Hanks G, Kaasa S, et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68

Diazgranados N, Ibrahim L, Brutsche NE, et al (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatmentresistant bipolar depression. Arch Gen Psychiatry 67:793–802

DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107

Ferrand E, Dreyfus JF, Chastrusse M, et al (2012) Évolution des demandes de mort anticipée exprimées auprès des équipes de soins palliatifs en France. L’enquête multicentrique DemandE. Med Palliat Soins Support — Accompagnement — Éthique 11:121–132

Goldberg RJ, Mor V (1985) A survey of psychotropic use in terminal cancer patients. Psychosomatics 26:745–748, 751

Haute Autorité de santé (2012) Avis de la commission de la transparence. Réévaluation des spécialités à base de méthylphénidate dans le trouble déficitaire de l’attention avec hyperactivité en réponse à la saisine de la Direction générale de la santé, 3 octobre

Haverkate I, Onwuteaka-Philipsen BD, van Der Heide A, et al (2000) Refused and granted requests for euthanasia and assisted suicide in the Netherlands: interview study with structured questionnaire. BMJ 321:865–866

Hotopf M, Chidgey J, Addington-Hall J, Lan Ly K (2002) Depression in advanced disease: a systematic review. Part 1. Prevalence and case finding. Palliat Med 16:81–97

Ibrahim L, Diazgranados N, Franco-Chaves J, et al (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37:1526–1533

Järventausta K, Chrapek W, Kampman O, et al (2013) Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J ECT 29:158–161

Kerr CW, Drake J, Milch RA, et al (2012) Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 43:68–77

Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107–111

Kudoh A, Takahira Y, Katagai H, Takazawa T (2002) Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 95:114–118, table of contents

Lépine JP, Gasquet I, Kovess V, et al (2005) Prévalence et comorbidité des troubles psychiatriques dans la population générale française: résultats de l’étude épidémiologique ESEMeD/MHEDEA 2000/ (ESEMeD). L’encéphale 31:182–194

Li N, Lee B, Liu RJ, et al (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959–964

Li N, Liu RJ, Dwyer JM, et al (2011) Glutamate N-methyl-Daspartate receptor antagonists rapidly reverse behavioural and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69:754–761

Li X, Jope RS (2010) Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 35:2143–2154

Lloyd-Williams M, Friedman T, Rudd N (1999) A survey of antidepressant prescribing in the terminally ill. Palliat Med 13:243–248

Lloyd-Williams M, Shiels C, Taylor F, Dennis M (2009) Depression—an independent predictor of early death in patients with advanced cancer. J Affect Disord 113:127–132

Loo CK, Katalinic N, Garfield JBB, et al (2012) Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord 142:233–240

Meier DE, Emmons CA, Litke A, et al (2003) Characteristics of patients requesting and receiving physician-assisted death. Arch Intern Med 163:1537–1542

Mitchell AJ, Chan M, Bhatti H, et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174

Monteggia LM, Gideons E, Kavalali ET (2013) The role of eukaryotic elongation factor 2-kinase in rapid antidepressant action of ketamine. Biol Psychiatry 73:1199–1203

Newport DJ, Nemeroff CB (1998) Assessment and treatment of depression in the cancer patient. J Psychosom Res 45:215–237

Organisation mondiale de la santé (2002) Définition OMS soins palliatifs [Internet]. [cité 5 juin 2013]

Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66:522–526

Rasmussen KG, Lineberry TW, Galardy CW, et al (2013) Serial infusions of low-dose ketamine for major depression. J Psychopharmacol Oxf Engl 27:444–450

Rayner L, Higginson IJ, Price A, Hotopf M (2010) The management of depression in palliative care: European Clinical Guidelines. Department of Palliative Care, Policy & Rehabilitation. European Palliative Care Research Collaborative, London

Rayner L, Price A, Evans A, et al (2011) Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med 25:36–51

Rayner L, Price A, Hotopf M, Higginson IJ (2011) The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer 47:702–712

Reich M, Razavi D (1996) Place des amphétamines en cancérologie: une revue de la littérature. Bull Cancer 83:891–900

Rhondali W, Perceau E, Berthiller J, et al (2012) Frequency of depression among oncology outpatients and association with other symptoms. Support Care Cancer 20:2795–2802

Rosenfeld KE, Wenger NS, Phillips RS, et al (1996) Factors associated with change in resuscitation preference of seriously ill patients. The Support Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Arch Intern Med 156:1558–1564

Temel JS, Greer JA, Muzikansky A, et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742

Thakurta RG, Das R, Bhattacharya AK, et al (2012) Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med 34:170–175

Ujeyl M, Müller-Oerlinghausen B (2012) Antidepressants for treatment of depression in palliative patients: a systematic literature review. Schmerz Berl Ger 26:523–536

Willner P, Scheel-Krüger J, Belzung C (2013) The neurobiology of depression and antidepressant action. Neurosci Biobehav 37:2331–2371

Zarate CA Jr, Brutsche NE, Ibrahim L, et al (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939–946

Zarate CA Jr, Singh JB, Carlson PJ, et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864